The earnings call reflects a generally positive outlook for Fulcrum Therapeutics. The company reported significant progress in clinical trials, particularly with their PIONEER trial for sickle cell disease, and financial improvements due to decreased expenses. However, the decrease in cash reserves and net loss are points of concern. Overall, the highlights outweigh the lowlights, suggesting a positive sentiment.

Company Guidance -

Q3 2025

During Fulcrum Therapeutics' First Quarter 2025 Financial Results and Business Update Conference Call, the company provided guidance on several key metrics. The Phase 1b PIONEER trial for their lead program, pociredir, completed enrollment in the 12 mg cohort with 16 patients, and results are expected in early Q3. The median fetal hemoglobin level at the study's start was 7.7%, with a mean of 7.6%. The trial boasts over 90% adherence to the once-daily regimen, and the Data Monitoring Committee recommended proceeding with the 20 mg cohort, with data also expected by the end of 2025. Financially, Fulcrum reported a net loss of $17.7 million for Q1 2025 and ended the quarter with $226.6 million in cash and equivalents. They anticipate these funds will suffice to support operations into at least 2027.

Successful Enrollment in Phase 1b PIONEER Trial

Fulcrum Therapeutics completed enrollment of the 12 milligram cohort in their Phase 1b PIONEER trial for sickle cell disease, with 16 patients enrolled. The trial is progressing to the 20 milligram cohort.

Positive Data Monitoring Committee Recommendation

The Data Monitoring committee recommended continuing the PIONEER study as planned after reviewing interim data from the 12 milligram cohort, allowing the initiation of the 20 milligram cohort.

Financial Improvements and Cost Reductions

Research and development expenses decreased by $6.4 million compared to the first quarter of 2024, attributed to the discontinuation of the losmapimod program and cost-sharing with Sanofi. General and administrative expenses also decreased by $3.1 million.

Strong Financial Position

Fulcrum ended the first quarter of 2025 with $226.6 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into at least 2027.

Upcoming Data Releases

Fulcrum plans to release data from the 12 milligram cohort in early Q3 and the 20 milligram cohort by the end of 2025, with additional presentations at the European Hematology Association meeting.

Fulcrum Therapeutics (FULC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FULC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.29 / -	-0.35	―	―	―
Jul 29, 2025	2025 (Q2)	-0.29 / -0.28	0.87	-132.18% (-1.15)	―	―
May 01, 2025	2025 (Q1)	-0.29 / -0.28	-0.43	34.88% (+0.15)	―
Feb 25, 2025	2024 (Q4)	-0.28 / -0.31	-0.4	22.50% (+0.09)	―
Nov 13, 2024	2024 (Q3)	-0.40 / -0.35	-0.39	10.26% (+0.04)	―
Jul 31, 2024	2024 (Q2)	-0.41 / 0.87	-0.38	328.95% (+1.25)	―
May 13, 2024	2024 (Q1)	-0.44 / -0.43	-0.41	-4.88% (-0.02)	―
Feb 27, 2024	2023 (Q4)	-0.43 / -0.40	-0.5	20.00% (+0.10)	―
Nov 07, 2023	2023 (Q3)	-0.44 / -0.39	-0.51	23.53% (+0.12)	―
Aug 03, 2023	2023 (Q2)	-0.45 / -0.38	-0.83	54.22% (+0.45)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FULC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$7.81	$7.59	-2.82%
May 01, 2025	$3.85	$4.38	+13.77%
Feb 25, 2025	$3.70	$3.70	0.00%
Nov 13, 2024	$3.64	$3.56	-2.20%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Fulcrum Therapeutics (FULC) report earnings?

Fulcrum Therapeutics (FULC) is schdueled to report earning on Nov 12, 2025, Before Open (Confirmed).

What is Fulcrum Therapeutics (FULC) earnings time?

Fulcrum Therapeutics (FULC) earnings time is at Nov 12, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is FULC EPS forecast?

FULC EPS forecast for the fiscal quarter 2025 (Q3) is -0.29.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing